Jyotishankar Raychaudhuri, MD

Raychaudhuri Jyotishankar
Specialties
Hematology, Bone Marrow Transplant
Primary Office
Address 801 N Flamingo Road
Suite 11
Pembroke Pines, FL 33028
Phone: 954-265-4325
Fax: 954-443-4747
Alternate Location
Address 20801 Biscayne Boulevard
Suite 200
Aventura, FL 33180
Phone: 954-265-4325
Fax: 305-935-3186

About Me

Dr. Jyotishankar Raychaudhuri is a blood and marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System.

Dr. Raychaudhuri earned his medical degree at All India Institute of Medical Sciences in New Delhi, India. He completed residencies in radiology and radiotherapy, internal medicine, and pathology in India, as well as a residency and fellowship in internal medicine at Lincoln Hospital, affiliated with New York Medical School. He completed another fellowship in hematology/oncology at Winthrop University Hospital in New York, and served as a post-doctoral fellow in a molecular biology and biochemistry lab at Cold Spring Harbor Laboratory in New York.

In addition to providing patient care, Dr. Raychaudhuri also teaches and trains medical students and young physicians. He has taught at various institutions including New York Medical College at Metropolitan Hospital, Cornell University Medical Center, Moffitt Cancer Center and USF College of Medicine.

He is also a manuscript reviewer for Clinical Myeloma and Lymphoma and a member of the Acute Leukemia Writing Committee, as part of the Center for International Blood & Marrow Transplant Research (CIBMTR).

Most recently, Dr. Raychaudhuri served as a senior consultant for Blood and Marrow Transplantation at Apollo Indraprastha Hospital in New Delhi, India. He has also served as assistant professor of Blood and Marrow Transplantation at the H. Lee Moffitt Cancer Center & Research Institute in Tampa. 

Related Medical Services

Education

Education
  • All India Institute Of Medical Sciences, 1988
Residencies
  • Lincoln Medical And Mental Health Ctr Prog, 1995, Internal Medicine
Fellowships
  • Lincoln Medical And Mental Health Ctr Prog, 1996
  • Winthrop University Hospital, 1999
Languages
  • Bengali

Professional Highlights

Professional Organizations

  • American College of Physicians
  • American Society of Hematology
  • American Society for Bone Marrow Transplantation

Presentations

  • Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan,(HD Mel) and BTZ as Conditioning regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma(MM) and Plasma Cell Leukemia (PCL). Biology of Blood and Marrow Transplantation February 2008 (Vol. 14, Issue 2, Page 68) ASBMT Feb 2008
  • Phase I/II trial of High-Dose Melphalan(M) and Topotecan(T) followed by Autologous Stem cell rescue in patients 60 years of age with Multiple Myeloma(MM) ASBMT Feb 2008
    Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Myelodysplastic Syndrome(MDS) after Pre-transplant 5-Azacytidine. ASBMT Feb 2008
  • Rituximab is Feasible to Administer to Allograft Recipients with Advanced CD20+ Malignancies and does not Affect Timely hematopoietic Engraftment. Biology of Blood and Marrow Transplantation February 2008 (Vol. 14, Issue 2, Pages 121-122) ASBMT Feb 2008
  • Treatment of Myeloid Malignancies in Elderly Patients with Fludarabine and Targeted Busulfan (t-Bu) and Allogeneic Hematopoietic cell Transplantation(HCT). Biology of Blood and Marrow Transplantation February 2008 (Vol. 14, Issue 2, Page 59) ASBMT Feb 2008
  • Long–term survival of Allogeneic Transplantation in Selected Patients with Multiple Myeloma: Disease free survival at two years may indicate long term survival : ASBMT Feb 2009
  • Age remains the strongest independent prognostic factor in patients with multiple myeloma undergoing autologous stem cell transplantation: Moffitt Cancer Center experience. ASBMT  Feb 2009
  • Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant. : ASBMT Feb 2009
  • Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); (VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma. Annual Meeting of the American Society of Hematology, 2009 Abstract 617 (oral presentation)
  • Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM). American Society of Clinical Oncology 2009, Abstract 8518 (oral Presentation). J Clin Oncol 27:15s, 2009 (suppl; abstr 8518)
  • Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2235
  • Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4323.
  • Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance Score (<80) at Day 90 Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory and Pharmacologic Parameters. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4329.
  • A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2235.
  • HyperCVAD+Bortezomib Is a Well Tolerated Salvage Regimen for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 4345.
  • Late Graft Failure in Allotransplants for Aplastic Anemia with Post transplant Cyclophosphamide may not need a Second Transplant – Recovery possible with only Increased Immunosuppression  ASBMT 2017 abstract 211; Feb 2017: page S169
 

Related Physicians